The taxoids. Comparative clinical pharmacology and therapeutic potential

Drugs

Volumn 55, Issue 1, 1998, Pages 5-30

  Eisenhauer, Elizabeth A ^a   Vermorken, Jan B ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CISPLATIN; DOCETAXEL; DOXORUBICIN; PACLITAXEL; PLATINUM DERIVATIVE; TAXOID;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; EDEMA; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; META ANALYSIS; METASTASIS; OVARY CANCER; PHASE 2 CLINICAL TRIAL; REVIEW; SKIN TOXICITY;

ALOPECIA; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE I; FEMALE; HUMANS; LUNG NEOPLASMS; NEOPLASMS; NEUTROPENIA; OVARIAN NEOPLASMS; PACLITAXEL; TAXOIDS;

EID: 0031973791     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199855010-00002     Document Type: Review

References (188)

1. Wani MC, Taylor HL, Wall ME, et al. Plant antitumour agents. VI: The isolution and structure of taxol: a novel antileukemic and antitumour agents from Taxus brevifolia. J Am Chem Soc 1971; 93: 2325-7
2. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979; 277: 665-7
3. Ringel I, Horwitz SB. Studies with RP 56976 (Taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 1991; 83: 288-91
4. Diaz JF, Andreu JM. Assembly of purified GDP-tubulin into microtubules induced by Taxol and Taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry 1993; 32: 2747-55
5. Andreu JM, Diaz JF, Gil R, et al. Solution structure of Taxotere-induced microtubules to 3-nm resolution: the change in protofilament number is linked to the binding of the taxol side chain. J Biol Chem 1994; 269: 31785-92
6. Riou JF, Petitgenet O, Combeau C, et al. Cellular uptake and efflux of docetaxel (Taxotere®) and paclitaxel (Taxol®) in P388 cell line [abstract]. Proc Am Assoc Cancer Res 1994; 35: 385
7. Lavelle F, Bissery MC, Combeau C, et al. Preclinical evaluation of docetaxel (Taxotere). Semin Oncol 1995; 22 Suppl. 4: 3-16
8. Rose WC. Taxol: a review of its preclinical in vivo antitumor activity. Anti-Cancer Drugs 1992; 3: 311-21
9. Donehower RC, Rowinsky EK, Grochow LB, et al. Phase I trial of taxol in patients with advanced cancer. Cancer Treat Rep 1487; 71: 1171-7
10. Hainsworth JD, Thompson DS, Greco FA. Paclitaxel by 1-hour infusion: an active drug in metastatic non-small cell lung cancer J Clin Oncol 1995; 13: 1609-4
11. Kris MG, O'Connel JP, Gralla R, et al. Phase I trial of taxol given as a 3-hour infusion every 21 days. Cancer Treat Rep 1986; 70: 605-7
12. Brown T, Havlin K, Weiss G, et al. A phase I trial of taxol given by a 6-hour intravenous infusion. J Clin Oncol 1991; 9: 1261-7
13. Wiernik PH, Schwartz EL, Straumann JJ, et al. Phase I clinical and pharmacokinetic study of taxol. Cancer Res 1987; 47: 2486-93
14. Ohnuma T, Zimet AS, Coffey VA, et al. Phase I study of taxol in a 24-hour infusion schedule [abstract]. Proc Am Assoc Cancer Res 1985; 26: 662
15. Wiernik PH, Schwartz EL, Einzig A, et al. Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol 1987; 5: 1232-9
16. Sarosy G, Kohn E, Stone DA, et al. Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 1992; 10: 1165-70
17. Spriggs DR, Tondini C. Taxol administered as a 120 hour infusion. Invest New Drugs 1992; 10: 275-8
18. Legha SS, Tenny DM, Krakow IR. Phase I study of taxol using a 5-day intermittent schedule. J Clin Oncol 1986; 4: 762-6
19. Grem JL, Tutsch KD, Simon KJ, et al. Phase I study of taxol administered as a short i.v. infusion daily for 5 days. Cancer Treat Rep 1987; 71: 1179-84
20. Wilson WH, Berg SL, Bryant G, et al. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol 1994; 12: 1621-9
21. Eisenhauer EA, ten Bokkel-Huinink WW, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12: 2654-66
22. Tange UB, Lund B, Hansen HH, et al. Phase I study of Taxotere (docetaxel) in patients (pts) with solid tumors [abstract]. Proc Am Soc Clin Oncol 1994; 13: 406
23. Extra JM, Rousseau F, Bruno R, et al. Phase I and pharmacokinetic study of Taxotere (RP56976; NSC 628503) given as a short intravenous infusion. Cancer Res 1993; 53: 1037-42
24. Tomiak E, Piccart MJ, Kerger J, et al. Phase I study of docetaxel administered as an intravenous 1-hour infusion on a weekly basis. J Clin Oncol 1994; 12: 1458-67
25. Burris HA, Irvin R, Kuhn J, et al. Phase I clinical trial of Taxotere administered as either a 2-hour or 6-hour infusion. J Clin Oncol 1993; 11: 950-8
26. Pazdur R, Newman RA, Newman BM, et al. Phase I trial of Taxotere, five day schedule. J Natl Cancer Inst 1992; 84: 1781-8
27. Bissett D, Setanoians A, Cassidy J, et al. Phase I and pharmacokinetic study of Taxotere (RP56976) administered as a 24-hour infusion. Cancer Res 1993; 53: 523-7
28. Piccart MJ, Klijn J, Paridaens R, et al. Steroids do reduce the severity and delay the onset of docetaxel (DXT) induced fluid retention: final results of a randomized trial of the EORTC Investigational Drug Branch for Breast Cancer (IDBBC) [abstract]. Eur J Cancer 1995; 31A Suppl. 5: S75
29. Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995; 13: 2688-99
30. Postma TJ, Vermorken JB, Liefting AJM, et al. Paclitaxel induced neuropathy. Ann Oncol 1995; 6: 489-94
31. Hilkens PH, Verweij J, Stoter G, et al. Peripheral neurotoxicity induced by docetaxel. Neurology 1996; 46: 104-8
32. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med 1995; 332: 1004-14
33. Huizing MT, Sewberath Misser VH, Pieters RC, et al. Taxanes: a new class of antitumor agents. Cancer Invest 1995; 13: 381-404
34. Huizing MT, Keung AC, Rosing H, et al. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum pretreated ovarian cancer patients. J Clin Oncol 1993; 11: 2127-35
35. Sonnichsen DS, Hurwitz CA, Pratt CB, et al. Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol 1994; 12: 532-8
36. Gianni L, Kearns CM, Giani A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995; 13: 180-90
37. Longnecker S, Ross D, Grochow L. High performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial. Cancer Treat Rep 1987; 71: 53-9
38. Lustig V, Rosing H, van Warmerdam LJC, et al. Limited sampling models for the pharmacokinetics of docetaxel. Clin Drug Treat 1997; 13: 247-54
39. 2 as a 3-hour infusion. Clin Drug Invest 1995; 9: 344-53
40. Bruno R, Vivien N, Vergniol JC, et al. A population pharmacokinetics model for docetaxel (Taxotere®): model building and validation. J Pharmacokinet Biopharm 1996; 2: 153-73
41. Walle T, Walle UK, Kumar GN, et al. Taxol metabolism and disposition in cancer patients. Drug Metab Disp 1995; 23: 506-12
42. Aapro MS, Zulian G, Alberto P, et al. Phase I and pharmacokinetic study of RP56976 in a new ethanol-free formulation of Taxotere [abstract]. Ann Oncol 1992; 3 Suppl. 5: 53
43. Paccaly D, Sanderink G, Paccaly-Moulin A, et al. Docetaxel (RP 56976, Taxotere®) human pharmacokinetics: technical summary. Rhone-Poulenc Rorer, 1994 Jul. (Data on file)
44. Huizing MT, Giaccone G, van Warmerdan LJC, et al. Pharmacokinetics of paclitaxel and carboplatin in a dose escalating and dose sequencing study in patients with non-small cell lung cancer. J Clin Oncol 1997; 15: 317-29
45. Huizing MT, Vermorken JB, Rosing H, et al. Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Center (ECC) trial. Ann Oncol 1995; 6: 699-704
46. Nannan Panday VR, Huizing MT, Willemse PHB, et al. Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function. Semin Oncol 1997; 24 Suppl. 11: S11-34-38
47. Venook AP, Egorin M, Brown JD, et al. Paclitaxel (Taxol) in patients with liver dysfunction (CALGB 9264) [abstract]. Proc Am Soc Clin Oncol 1994; 13: 139
48. Huizing MT, Rosing H, Vermorken JB, et al. Pharmacology of paclitaxel (P) and metabolites in patients with altered liver function [abstract]. Eur J Cancer 1995; 31A Suppl. 5: S192
49. Bruno R, Hille D, Thomas L, et al. Population pharmacokinetics/pharmacodynamics of docetaxel (Taxotere®) [abstract]. Proc Am Soc Clin Oncol 1995; 14: 457
50. Fulton B, Spencer CM. Docetaxel: a review of the pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. Drugs 1996 Jun; 51 (6): 1075-92
51. Rowinsky EK, Gilbert MR, McGuire WP, et al. Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 1991; 9: 1691-703
52. Kennedy MJ, Zahurak ML, Donehower RC, et al. Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony stimulating factor in women with previously untreated breast cancer. J Clin Oncol 1996; 14: 783-91
53. Holmes FA, Valero V, Walters RS, et al. The M.D. Anderson Cancer Center experience with Taxol in metastatic breast cancer. Monogr Natl Cancer Inst 1993; 15: 161-9
54. Sledge Jr GW. Doxorubicin/paclitaxel combination chemotherapy for metastatic breast cancer: the Eastern Cooperative Oncology Group experience. Semin Oncol 1995; 22: 123-5
55. Holmes FA, Newman EA, Madden T, et al. Schedule dependent pharmacokinetics in a phase I trial of taxol and doxorubicin as initial chemotherapy for metastatic breast cancer [abstract]. Ann Oncol 1994; 5: 191
56. Gianni L, Vigano L, Locarelli A, et al. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 1997; 15: 1906-15
57. Pronk LC, Schellens JHM, Planting AST, et al. Phase I and pharmacokinetic study of docetaxel and cisplatin in patients with advanced solid tumors. J Clin Oncol 1997; 15: 1071-9
58. Schellens JHM, Ma J, Bruno R, et al. Pharmacokinetics of cisplatin and Taxotere® (docetaxel) and WBC DNA-adduct formation of cisplatin in the sequence Taxotere®/cisplatin and cisplatin/Taxotere® in a phase I/II study in solid tumor patients [abstract]. Proc Am Soc Clin Oncol 1994; 13: 132
59. Holmes FA, Walters RS, Theriault RL, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991; 83: 1797-805
60. Reichman BS, Seidman AD, Crown JPA, et al. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1993; 11: 1943-51
61. Swain SM, Honig SF, Tefft MC, et al. A phase II trial of paclitaxel (Taxol®) as first-line treatment in advanced breast cancer. Invest New Drugs 1945; 13: 217-2
62. 2 over 3 hours q 21 days in patients (pts) failing initial therapy for breast cancer [abstract]. Proceedings of the Sixth International Congress on Anti-Cancer Treatment 1995; 5: 119
63. Gianni L, Munzone E, Capri G, et al. Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 1995; 87: 1169-75
64. Seidman AD, Tiersten A, Hudis C, et al. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 1995; 13: 2575-81
65. Fountzilas G, Athanassiades A, Giannakakis T, et al. A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines. Eur J Cancer 1996; 32A: 47-51
66. Nabholtz JM, Gelmon K, Bontenbal M, et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996; 14: 1858-67
67. Peretz T, Sulkes A, Chollet P, et al. A multicenter, randomized study of two schedules of paclitaxel (PTX) in patients with advanced breast cancer (ABC) [abstract]. Eur Cancer 1995; 31A Suppl. 5: S75
68. Seidman AD, Reichman BS, Crown JPA, et al. Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 1995; 13: 1152-9
69. Seidman AD, Hochhauser D, Gollub M, et al. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol 1996; 14: 1877-84
70. Abrams JS, Vena DA, Baltz J, et al. Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute treatment referral center trial. J Clin Oncol 1995; 13: 2056-65
71. Hudis CA, Seidman AD, Crown JPA, et al. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14: 58-65
72. Trudeau ME, Eisenhauer EA, Higgins BP. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996; 14: 422-8
73. Chevallier B, Fumoleau P, Kerbrat P, et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 1995; 13: 314-22
74. Dieras V, Fumoleau P, Chevallier B et al. Second EORTC-Clinical Screening Group (CSG) phase II trial of Taxotere® (docetaxel) as first-line chemotherapy (CT) in advanced breast cancer (ABC) [abstract]. Proc Am Soc Clin Oncol 1994; 13: 78
75. Fumoleau P, Chevallier B, Kerbrat P, et al. A multicentre phase II study of the safety and efficacy of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC. Ann Oncol 1996: 7: 165-71
76. ten Bokkel Huinink WW, Prove AM, Piccart M, et al. A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. Ann Oncol 1994; 5: 527-32
77. Adachi I, Watanabe T, Takashima S, et al. A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer. Br J Cancer 1996; 73: 210-6
78. Valero V, Holmes FA, Walters RS, et al: Phase II trial of docetaxel (Taxotere®): a highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995; 13: 2886-94
79. Ravdin PM, Burris HA, Cook G, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995; 13: 2879-85
80. Guastalla JP, Bonneterre J, Fumoleau P, et al. A phase II trial of docetaxel in patients with anthracycline resistant metastatic breast cancer [abstract]. Eur J Cancer 1995; 31A Suppl. 5: S75
81. Paridaens R, Bruning P, Klijn J, et al. An EORTC crossover trial comparing Taxol (T) and doxorubicin (D) as first- and second-line chemotherapy (CT) in advanced breast cancer [abstract]. Proc Am Soc Clin Oncol 1997; 16: 154a
82. Chan S, Friedrichs K, Noel D, et al. A randomized phase III study of Taxotere (T) versus doxorubicin (D) in patients (pts) with metastatic breast cancer (MBC) who have failed an alkylating containing regimen: preliminary results [abstract]. Proc Am Soc Clin Oncol 1997; 16: 154a
83. Fisherman JS, Cowan KH, Noone M, et al. Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte-colony stimulating factor in patients with metastatic breast cancer. J Clin Oncol 1996; 14: 774-82
84. Gelmon KA, O'Reilly SE, Tolcher AW, et al. Phase I/II trial of bi-weekly paclitaxel and cisplatin in the treatment of metastatic breast cancer. J Clin Oncol 1996; 14: 1185-91
85. Gehl J, Boesgaard M, Paaske T, et al. Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol 1996; 7: 687-93
86. Conte PF, Baldini E, Gennari A, et al. Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer. J Clin Oncol 1997; 15: 2510-7
87. Bourgeois H, Gruia G, Dieras V, et al. Docetaxel in combination with doxorubicin as first-line chemotherapy of metastatic breast cancer: a phase I dose-finding study [abstract]. Proc Am Soc Clin Oncol 1996; 15: 148
88. Sledge Jr GW, Neuberg D, Ingle J, et al. Phase III trial of doxorubicin (A) vs. paclitaxel (T) vs. doxorubicin + paclitaxel (A + T) as first-line therapy for metastatic breast cancer (MBC): an intergroup trial [abstract]. Proc Am Soc Clin Oncol 1997; 16: 1a
89. Bishop JF, Dewar J, Tattersall MHN, et al. Taxol® (paclitaxel) alone is equivalent to CMFP combination chemotherapy as frontline treatment in metastatic breast cancer [abstract]. Proc Am Soc Clin Oncol 1997; 16: 153a
90. McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989; 111: 273-9
91. Einzig AI, Wiernik PH, Sasloff J, et al. Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol 1992; 10: 1748-53
92. Thigpen JT, Blessing JA, Ball H, et al. Phase II trial of paclitaxel in patients with progressive for ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group Study. J Clin Oncol 1994; 12: 1748-53
93. Seewaldt VL, Greer BE, Cain JM, et al. Paclitaxel (Taxol) treatment for refractory ovarian cancer: phase II clinical trial. Am J Obstet Gynecol 1994; 170: 1666-70
94. Gore ME, Levy V, Rustin G, et al. Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience. Br J Cancer 1995; 72: 1016-9
95. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6
96. Piccart MJ, Bertelsen K, Stuart G, et al. Is cisplatin-paclitaxel (P-T) the standard in first-line treatment of advanced ovarian cancer (OvCa)? The EORTC-GCCG, NOCOVA, NCI-C, and Scottish Intergroup experience [abstract]. Proc Am Soc Clin Oncol 1997; 16: 352a
97. Muggia FM, Braly PS, Brady MF, et al. Phase III study of cisplatin (P) or paclitaxel (T) versus their combination in suboptimal stage III and IV epithelial ovarian cancer (EOC): Gynecologic Oncology Group (GOG) study #132 [abstract]. Proc Am Soc Clin Oncol 1997; 16: 352a
98. Bookman MA, McGuire WP, Kilpatrick D, et al. Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. J Clin Oncol 1996; 14: 1895-902
99. Bolis G. Pilot study with fixed-dose carboplatin and escalating paclitaxel in advanced ovarian cancer. Semin Oncol 1995; 22 (6 Suppl. 14): 32-4
100. ten Bokkel Huinink W, Veenhof, Helmerhorst T, et al. Paclitaxel plus carboplatin in the treatment of ovarian cancer. Semin Oncol 1995; 22 (3 Suppl. 6): 97-100
101. Giaccone G, Huizing M, ten Bokkel Huinink W, et al. Preliminary results of two dose-finding studies of paclitaxel (Taxol) and carboplatin in non-small cell lung and ovarian cancers. Semin Oncol 1994; 21 (5 Suppl. 8): 34-8
102. Calvert AH, Boddy A, Bailey NP, et al. Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions. Semin Oncol 1995; 22 (5 Suppl. 12): 91-8
103. Neijt JP, Hansen M, Hansen SW, et al. Randomized phase III study in previously untreated epithelial ovarian cancer FIGO stage IIB, IIC, III, IV, comparing paclitaxel-cisplatin and paclitaxel-carboplatin [abstract]. Proc Am Soc Clin Oncol 1997; 16: 352a
104. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot study. J Clin Oncol 1995; 13: 2961-7
105. Vermorken JB, Huijskes R, Hoekman K, et al. Feasibility and efficacy of a 2-weekly taxol, epirubicin and cisplatin (TEC) regimen in patients with advanced ovarian cancer (ADOVCA) [abstract]. Proc Am Assoc Cancer Res 1996; 37: 169
106. Francis P, Schneider J, Hann L, et al. Phase II trial of docetaxel in patients with platinum refractory ovarian cancer. J Clin Oncol 1994; 12: 2301-8
107. Piccart MJ, Gore M, ten Bokkel Huinink W, et al. Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancel. J Natl Cancer Inst 1995; 87: 676-81
108. Chang AY, Kim K, Glick J, et al. Phase II study of taxol, merbarone and piroxantrone in stage IV non-small cell lung cancer: the Eastern Cooperative Oncology Group results. J Natl Cancer Inst 1993; 85: 388-94
109. Murphy WK, Fossella FV, Winn RJ, et al. Phase II study of taxol in patients with untreated advanced non-small cell lung cancer. J Natl Cancer Inst 1993; 85: 384-8
110. Gatzmeier U, Heckmayr M, Neuhauss R, et al. Phase II study of paclitaxel for the treatment of advanced inoperable non-small cell lung cancer. Lung Cancer 1995; 12 Suppl. 2: S101-6
111. Sekine I, Nishiwaki Y, Watanabe K, et al. Phase II study of 3-hour infusion of paclitaxel in previously untreated non-small cell lung cancer. Clin Cancer Res 1996; 2: 941-5
112. Millward MJ, Bishop JF, Friedlander M, et al. Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small cell lung cancer. J Clin Oncol 1996; 14: 142-8
113. Murphy WK, Winn RJ, Huber M, et al. Phase II study of Taxol in patients with non-small cell lung cancer who have failed platinum containing chemotherapy [abstract]. Proc Am Soc Clin Oncol 1994; 13: 363
114. Ruckdeschel J, Wagner Jr H, Williams C, et al. Second-line chemotherapy for resistant, metastatic, non-small cell lung cancer (NSCLC): the role of Taxol [abstract]. Proc Am Soc Clin Oncol 1994; 13: 357
115. Fossella FV, Lee JS, Murphy WK, et al. Phase II study of docetaxel for recurrent or metastatic non-small cell lung cancer. J Clin Oncol 1994; 12: 1238-44
116. Francis PA, Rigas JR, Kris MG, et al. Phase II trial of docetaxel in patients with stage III and IV non-small cell lung cancer. J Clin Oncol 1994; 12: 1232-7
117. Cerny T, Kaplan S, Pavlidis N, et al. Docetaxel (Taxotere®) is active in non-small cell lung cancer: a phase II study of the EORTC early clinical trials group (ECTG). Br J Cancer 1994; 70: 384-7
118. Burris H, Eckardt J, Fields S, et al. Phase II trials of Taxotere in patients with non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 1993; 12: 335
119. 2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer 1995; 75: 968-72
120. Kunitoh H, Watanabe K, Onoshi T, et al. Phase II trial of docetaxel in previously untreated advanced non-small cell lung cancer: a Japanese cooperative group study. J Clin Oncol 1996; 14: 1649-55
121. Fossella FV, Lee JS, Shin DM, et al. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small cell lung cancer. J Clin Oncol 1995; 13: 645-51
122. Langer CJ, Leighton JC, Comis RL, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer (NSCLC): a phase II toxicity, response and survival analysis. J Clin Oncol 1995; 13: 1860-70
123. Johnson DH, Paul DM, Hande KR, et al. Paclitaxel plus carboplatin in advanced non-small cell lung cancer a phase II trial. J Clin Oncol 1996; 14: 2054-60
124. Shepherd FA, Latreille J, Crump M, et al. A phase I study of paclitaxel and ifosfamide in advanced non-small cell lung cancer. Ann Oncol 1996; 7: 311-3
125. Chang AY, DeVore R, Johnson D. Pilot study of vinorelbine and paclitaxel in patients with refractory non-small cell lung cancer. Semin Oncol 1996; 23 (2 Suppl. 5): 19-21
126. Choy H, Akerley W, Safran H, et al. Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small cell lung cancer. J Clin Oncol 1994; 12: 2682-6
127. Kirkbride P, Eisenhauer E, Gelmon K, et al. Phase I trial of paclitaxel (Tax) and radical radiotherapy (XRT) in patients (pts) with stage III non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 1996; 15: 392
128. Bonomi P, Kim K, Chang A, et al. Phase III trial comparing etoposide (E) cisplatin (C) versus Taxol (T) with cisplatin-G-CSF (G) versus Taxol-cisplatin in advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group (ECOG) trial [abstract]. Proc Am Soc Clin Oncol 1996; 15: 382
129. Giaccone G, Postmus P, Debruyne C, et al. Final results of an EORTC phase III study of paclitaxel versus teniposide, in combination with cisplatin, in advanced NSCLC [abstract]. Proc Am Soc Clin Oncol 1997; 16: 460a
130. LeChevalier T, Belli F, Monnier A, et al. Phase II study of docetaxel (Taxotere) and cisplatin in advanced non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 1995; 14: 350
131. Cole JT, Gralla RJ, Marques CB, et al. Phase I-II study of cisplatin + docetaxel (Taxotere) in non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 1995; 14: 357
132. Kourousis C, Kakolyris S, Androullakis N, et al. First-line treatment on non-small cell lung carcinoma with docetaxel and vinorelbine: a phase II study [abstract]. Proc Am Soc Clin Oncol 1996; 15: 405
133. Masters GA, Haraf DJ, Hoffman PC, et al. Phase I study of concomitant docetaxel (Taxotere, TXT) and radiation (RT) in advanced chest malignancies [abstract]. Proc Am Soc Clin Oncol 1996; 15: 374
134. Ettinger DS, Finkelstein DM, Sarma RP, et al. Phase II study of paclitaxel in patients with extensive-disease small cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1995; 13: 1430-5
135. Kirschling RJ, Jung SH, Jett JR. A phase II study of Taxol and G-CSF in previously untreated patients with extensive stage small cell lung cancer (SCC) [abstract]. Proc Am Soc Clin Oncol 1994; 13: 326
136. Smit EF, Kloosterziel C, Groen HJM, et al. A phase II study of paclitaxel (P) in heavily pretreated patients with small cell lung cancel (SCLC) [abstract]. Proc Am Soc Clin Oncol 1996; 15: 394
137. Latreille J, Cormier Y, Martins H, et al. Phase II study of docetaxel (Taxotere) in patients with previously untreated extensive small cell lung cancer. Invest New Drugs 1996; 13: 343-5
138. Smyth JF, Smith IE, Sessa C, et al. Activity of docetaxel (Taxotere) in small cell lung cancer. Eur J Cancer 1994; 30A: 1058-60
139. Forastiere AA. Current and future trials of Taxol (paclitaxel) in head and neck cancer. Ann Oncol 1995; 5 Suppl. 6: S51-4
140. Thornton D, Singh K, Putz B, et al. A phase II trial of taxol in squamous cell carcinoma of the head and neck [abstract]. Proc Am Soc Clin Oncol 1994; 13: 288
141. Gebbia V, Testa A, Cannata G, et al. Single agent paclitaxel in advanced squamous cell head and neck carcinoma. Eur J Cancer 1996; 32A: 901-2
142. Catimel G, Verweij J, Mattijson V, et al. Docetaxel (Taxotere®): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 1994; 5: 533-7
143. Dreyfuss AI, Clark JR, Norris CM, et al. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 1996; 14: 1672-8
144. Couteau C, Leyvraz S, Oulid-Aissa D, et al. A phase II study of docetaxel in squamous cell carcinoma (SCC) of the head and neck [abstract]. Proc Am Soc Clin Oncol 1996; 15: 315
145. Ebihara S, Fujii M, Sasaki Y, et al. A late phase II study of docetaxel (Taxotere®) in patients with head and neck cancer (HNC) [abstract]. Proc Am Soc Clin Oncol 1997; 16: 399a
146. Vermorken JB, Catimel G, Stupp R, et al. Randomized phase II trial of methotrexate (MTX) versus two schedules of Taxol (T) in patients with advanced squamous cell carcinoma of the head and neck [abstract]. Proc Am Soc Clin Oncol 1997; 16: 410a
147. Fujii H, Sasaki Y, Ebihara S, et al. An early phase II study of docetaxel (Taxotere®) in patients with head and neck cancer [abstract]. Proc Am Soc Clin Oncol 1994; 14: 298
148. Jekunen AP, Christen RD, Shalinsky DR, et al. Synergistic in teraction between cisplatin and Taxol in human ovarian carcinoma cells in vitro. Br J Cancer 1994; 69: 299-306
149. Forastiere AA, Leong T, Murphy B, et al. A phase III trial of high-dose paclitaxel + cisplatin + G-CSF versus low dose paclitaxel + cisplatin in patients with advanced squamous cell carcinoma of the head and neck (HNSCC): an Eastern Cooperative Oncology Group trial [abstract]. Proc Am Soc Clin Oncol 1997; 16: 384a
150. Hitt R, Hornedo J, Colomer R, et al. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results. Semin Oncol 1995; 22 Suppl. 15: 50-4
151. Schoffski P, Wanders J, Catimel G, et al. Docetaxel and cisplatin: a highly active regimen for squamous cell carcinoma of the head and neck [abstract]. Proc Am Soc Clin Oncol 1996; 15: 310
152. Posner M, Norris C, Colevas A, et al. Phase I/II trial of docetaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) for curable, locally advanced squamous cell cancer of the head and neck (SCCHN) [abstract]. Proc Am Soc Clin Oncol 1997; 16: 387a
153. Bruntsch U, Heinrich B, Kaye SB, et al. Docetaxel (Taxotere) in advanced renal cell cancer: a phase II trial of the EORTC Early Clinical Trials Group. Eur J Cancer 1994; 30A: 1064-7
154. Mertens WC, Eisenhauer EA, Jolivet J, et al. Docetaxel in advanced renal carcinoma: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 1994; 5: 185-7
155. Pazdur R, Lassere Y, Soh LT, et al. Phase II trial of docetaxel (Taxotere®) in metastatic colorectal cancer. Ann Oncol 1994; 5: 468-70
156. Sternberg CN, ten Bokkel Huinink WW, Smyth JF, et al. Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group study. Br J Cancer 1994; 70: 376-9
157. Legha SS, Ring S, Papadopoulos N, et al. A phase II trial of taxol in metastatic melanoma. Cancer 1990; 65: 2478-81
158. Einzig A, Hochster H, Wiernik PH, et al. A phase II study of taxol in patients with malignant melanoma. Invest New Drugs 1991; 9: 59-64
159. Bedikian AY, Weiss GR, Legha SS, et al. Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. J Clin Oncol 1995; 13: 2895-9
160. Aamdal S, Wolff I, Kaplan S, et al. Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group. Eur J Cancer 1994; 30A: 1061-4
161. Einzig AI, Schuchter LM, Wadler S, et al. Phase II trial of Taxotere (RP 56976) in patients (pts) with metastatic melanoma previously untreated with cytotoxic chemotherapy [abstract]. Proc Am Soc Clin Oncol 1994; 13: 395
162. McGuire WP, Blessing JA, Moore D, et al. Paclitaxel has moderate activity in squamous cervix cancer: a Gynecologic Oncology Group study. J Clin Oncol 1996; 14: 792-5
163. 2 administered intravenously (IV) over 3h every 21 days with G-CSF support [abstract]. Proc Am Soc Clin Oncol 1996; 15: 281
164. Kudelka AP, Verschraegen CF, Levy T, et al. Preliminary report of the activity of docetaxel in advanced or recurrent squamous cell cancer of the cervix. Anti Cancer Drugs 1996; 7: 398-401
165. Prados MD, Schold SC, Spence AM, et al. Phase II study of paclitaxel in patients with recurrent malignant glioma. J Clin Oncol 1996; 14: 2316-21
166. Chamberlain MC, Kormanink P. Salvage chemotherapy with paclitaxel for recurrent primary brain tumors. J Clin Oncol 1995; 13: 2066-71
167. Forsyth P, Cairncross G, Stewart D, et al. Phase II trial of docetaxel in patients with recurrent malignant glioma. Invest New Drugs 1996; 14: 203-6
168. Glantz MJ, Choy H, Kearns CM, et al. Phase I study of weekly outpatient paclitaxel and concurrent irradiation in adults with astrocytomas. J Clin Oncol 1996; 14: 600-9
169. van Hoesel QGCM, Verweij J, Catimel G, et al. Phase II study with docetaxel (Taxotere™) in advanced soft tissue sarcomas of the adult. Ann Oncol 1994; 5: 539-42
170. Blackstein M, Eisenhauer EA, Bramwell V, et al. Docetaxel (Taxotere) as first line therapy for metastatic or recurrent soft tissue sarcoma (STS): a Phase II Trial of the National Cancer Institute of Canada Clinical Trials Group [abstract]. Eur J Cancer 1995; 31A Suppl. 5: S177
171. Waltzman R, Schwartz GK, Shorter S, et al. Lack of efficacy of paclitaxel (Taxol) in patients with advanced soft tissue sarcoma (STS) [abstract]. Proc Am Soc Clin Oncol 1996; 15: 526
172. Ajani JA, Ilson DH, Daugherty K, et al. Activity of Taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 1994; 86: 1086-91
173. Einzig AV, Lipsitz S, Wiernik PH, et al. Phase II trial of Taxol in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT). Invest New Drugs 1995; 13: 223-7
174. Einzig AI, Lipsitz S, Wiernik PJ, et al. Phase II trial of Taxotere in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT) previously untreated with cytotoxic chemotherapy: the Easter Cooperative Oncology Group (ECOG) results [abstract]. Proc Am Soc Clin Oncol 1995; 14: 191
175. Sulkes A, Smyth J, Sessa C, et al. Docetaxel (Taxotere™) in advanced gastric cancer: results of a phase II clinical trial. Br J Cancer 1994; 70: 380-3
176. Roth BJ, Dreicer R, Einhorn LH, et al. Significant activity of paclitaxel in advanced transitional cell carcinoma or the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 1994; 12: 2264-70
177. Dreicer R, Gustin D, See WA, et al. Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy [abstract]. Proc Am Soc Clin Oncol 1996; 15: 242
178. McCaffrey J, Hilton S, Bajorin D, et al. Docetaxel in patients with advanced transitional cell cancer (TCC) who failed cisplatin based chemotherapy [abstract]. Proc Am Soc Clin Oncol 1995; 14: 233
179. Christou A, Roth B, Fox S, et al. Phase II trial of paclitaxel in refractory germ cell neoplasms [abstract]. Proc Am Soc Clin Oncol 1996; 15: 249
180. Bokemeyer C, Beyer J, Metzner B, et al. Phase II study of paclitaxel in patients with relapsed or cisplatin refractory testicular cancer. Ann Oncol 1996; 7: 31-4
181. Motzer RJ, Bajorin DF, Schwartz LH, et al. Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 1994; 12: 2277-83
182. Thigpen T, Vance RB, Khansur T. The platinum compounds and paclitaxel in the management of carcinomas of the endometrium and uterine cervix. Semin Oncol 1995; 22: 67-75
183. Woo HL, Swenerton KD, Hoskins PJ. Taxol is active in platinum-resistant endometrial adenocarcinoma. Am J Clin Oncol 1996; 19: 290-1
184. Wilson WH, Chabner BA, Bryant G, et al. Phase II study of paclitaxel in relapsed non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 381-6
185. Younes A, Sarris A, Melnyk A, et al. Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 583-7
186. Younes A, Ayoub J-P, Hagemeister FB, et al. No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour schedule. J Clin Oncol 1996; 14: 543-8
187. Goss P, Stewart A, Couture F, et al. A phase II study of paclitaxel in patients with refractory lymphomas [abstract]. Proc Am Soc Clin Oncol 1996; 15: 419
188. Dimopoulos MA, Arbuck S, Huber M, et al. Primary therapy of multiple myeloma with paclitaxel (Taxol). Ann Oncol 1994; 5: 757-9